Figure 2. Sorafenib and Vorinostat interact to kill GBM cells. (A) GBM5 cells were treated with vehicle or Vorinostat (0.4 μM; 0.8 μM). Thirty minutes later cells were treated with vehicle or sorafenib (3 μM; 6 μM). Cells were isolated 24 h later. Viability was determined by trypan blue exclusion (n = 3, ± SEM) *p < 0.05 greater than corresponding vehicle control treated cells. (B) GBM14 cells were treated with vehicle or Vorinostat (0.4 μM; 0.8 μM). Thirty minutes later cells were treated with vehicle or sorafenib (3 μM; 6 μM). Cells were isolated 24 h later. Viability was determined by trypan blue exclusion (n = 3, ± SEM) *p < 0.05 greater than corresponding vehicle control treated cells. (C) GBM12 cells were treated with vehicle or Vorinostat (0.4 μM; 0.8 μM). Thirty minutes later cells were treated with vehicle or sorafenib (3 μM; 6 μM). Cells were isolated 24 h later. Viability was determined by trypan blue exclusion (n = 3, ± SEM) *p < 0.05 greater than corresponding vehicle control treated cells.